NCT07063758 - A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

December 31, 2029

Conditions

Advanced Urothelial Carcinoma

Interventions

OTHER

Biomarker Analysis

Tumor tissue and serum samples will be collected and analyzed to evaluate the expression of membranous Nectin-4, ADAM10/17, and levels of soluble Nectin-4 (sNectin-4) as predictive biomarkers in patients with advanced urothelial carcinoma receiving standard therapies.

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Clinical Trial Center

OTHER